References
- Osterberg L, Blaschke T. Adherence to medication. N. Engl J Med 2005;353:487-97
- Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
- Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; (2):CD000011
- Kripalani S. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540-549
- Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
- Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States. A systematic review. Ann Intern Med 2012; doi: 10.7326/0003-4819-157-11-201212040-00538. [Epub ahead of print]
- Cutler DM, Everett W. Thinking outside the pillbox – medication adherence as a priority for health care reform. N Engl J Med 2010;362:1553-5
- Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Affairs 2007;26:97-110
- Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
- Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
- Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48
- Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012;50:870-5
- Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
- Zhang Y, Lave JR, Donohue JM. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care 2010;48:409-17
- Yang M, Barner JC, Worchel J. Factors related to antipsychotic oversupply among Central Texas Veterans. Clin Ther 2007;29:1214-25
- Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46:1-7
- Oleen-Burkey MA, Dor A, Castelli-Haley J, et al. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ 2011;14:739-47
- Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
- Grundy SM. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
- Gotto AM, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. Circulation 1999;99:e1-7
- Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J American Coll Cardiol 2009;53:316-22
- Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-19
- Kastelein JJP, Van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9
- Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff 2012;31:2276-85